Targets › MIR126
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2028.
Open in Phaseline: the race on MIR126, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | miRisten miR-126 inhibitor; CpG-linked anti-miR-126 oligonucleotide | MIR126 | Phase 1 | Recurrent Acute Myeloid Leukemia | Mar 2028 |
Recurrent Acute Myeloid Leukemia (1)
other (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.